1,680 reports of this reaction
1.9% of all OLANZAPINE PAMOATE reports
#6 most reported adverse reaction
HYPERTENSION is the #6 most commonly reported adverse reaction for OLANZAPINE PAMOATE, manufactured by H2-Pharma LLC. There are 1,680 FDA adverse event reports linking OLANZAPINE PAMOATE to HYPERTENSION. This represents approximately 1.9% of all 88,377 adverse event reports for this drug.
OLANZAPINE PAMOATE has an overall safety score of 85 out of 100. Patients taking OLANZAPINE PAMOATE who experience hypertension should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
HYPERTENSION is a less commonly reported adverse event for OLANZAPINE PAMOATE, but still significant enough to appear in the safety profile.
In addition to hypertension, the following adverse reactions have been reported for OLANZAPINE PAMOATE:
The following drugs have also been linked to hypertension in FDA adverse event reports:
HYPERTENSION has been reported as an adverse event in 1,680 FDA reports for OLANZAPINE PAMOATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
HYPERTENSION accounts for approximately 1.9% of all adverse event reports for OLANZAPINE PAMOATE, making it a notable side effect.
If you experience hypertension while taking OLANZAPINE PAMOATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.